BLISSGVS: Quarterly revenue and profit grew modestly, with stable performance in core pharma operations

About this update from Bliss Gvs Pharma Limited

Consolidated revenue and net profit for the quarter ended December 31, 2024, showed modest year-over-year growth, with continued focus on the pharmaceutical and healthcare segment. Statutory auditors issued unmodified review reports. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Bliss Gvs Pharma Limited